Influenza Vaccine in Heart Failure: Cumulative Number of Vaccinations, Frequency, Timing, and Survival: A Danish Nationwide Cohort Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Influenza Vaccine in Heart Failure : Cumulative Number of Vaccinations, Frequency, Timing, and Survival: A Danish Nationwide Cohort Study. / Modin, Daniel; Jørgensen, Mads Emil; Gislason, Gunnar; Jensen, Jan Skov; Køber, Lars; Claggett, Brian; Hegde, Sheila M.; Solomon, Scott D.; Torp-Pedersen, Christian; Biering-Sørensen, Tor.

I: Circulation, Bind 139, Nr. 5, 2019, s. 575-586.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Modin, D, Jørgensen, ME, Gislason, G, Jensen, JS, Køber, L, Claggett, B, Hegde, SM, Solomon, SD, Torp-Pedersen, C & Biering-Sørensen, T 2019, 'Influenza Vaccine in Heart Failure: Cumulative Number of Vaccinations, Frequency, Timing, and Survival: A Danish Nationwide Cohort Study', Circulation, bind 139, nr. 5, s. 575-586. https://doi.org/10.1161/CIRCULATIONAHA.118.036788

APA

Modin, D., Jørgensen, M. E., Gislason, G., Jensen, J. S., Køber, L., Claggett, B., Hegde, S. M., Solomon, S. D., Torp-Pedersen, C., & Biering-Sørensen, T. (2019). Influenza Vaccine in Heart Failure: Cumulative Number of Vaccinations, Frequency, Timing, and Survival: A Danish Nationwide Cohort Study. Circulation, 139(5), 575-586. https://doi.org/10.1161/CIRCULATIONAHA.118.036788

Vancouver

Modin D, Jørgensen ME, Gislason G, Jensen JS, Køber L, Claggett B o.a. Influenza Vaccine in Heart Failure: Cumulative Number of Vaccinations, Frequency, Timing, and Survival: A Danish Nationwide Cohort Study. Circulation. 2019;139(5):575-586. https://doi.org/10.1161/CIRCULATIONAHA.118.036788

Author

Modin, Daniel ; Jørgensen, Mads Emil ; Gislason, Gunnar ; Jensen, Jan Skov ; Køber, Lars ; Claggett, Brian ; Hegde, Sheila M. ; Solomon, Scott D. ; Torp-Pedersen, Christian ; Biering-Sørensen, Tor. / Influenza Vaccine in Heart Failure : Cumulative Number of Vaccinations, Frequency, Timing, and Survival: A Danish Nationwide Cohort Study. I: Circulation. 2019 ; Bind 139, Nr. 5. s. 575-586.

Bibtex

@article{987404f7cf5647029fcb8e68bce3641d,
title = "Influenza Vaccine in Heart Failure: Cumulative Number of Vaccinations, Frequency, Timing, and Survival: A Danish Nationwide Cohort Study",
abstract = "Background: Influenza infection is a serious event for patients with heart failure (HF). Little knowledge exists about the association between influenza vaccination and outcome in patients with HF. This study sought to determine whether influenza vaccination is associated with improved long-term survival in patients with newly diagnosed HF. Methods: We performed a nationwide cohort study including all patients who were >18 years of age and diagnosed with HF in Denmark in the period of January 1, 2003, to June 1, 2015 (n=134 048). We collected linked data using nationwide registries. Vaccination status, number, and frequency during follow-up were treated as time-varying covariates in time-dependent Cox regression. Results: Follow-up was 99.8% with a median follow-up time of 3.7 years (interquartile range, 1.7-6.8 years). The vaccination coverage of the study cohort ranged from 16% to 54% during the study period. In unadjusted analysis, receiving ≥1 vaccinations during follow-up was associated with a higher risk of death. After adjustment for inclusion date, comorbidities, medications, household income, and education level, receiving ≥1 vaccinations was associated with an 18% reduced risk of death (all-cause: hazard ratio, 0.82; 95% CI, 0.81-0.84; P<0.001; cardiovascular causes: hazard ratio, 0.82; 95% CI, 0.81-0.84; P<0.001). Annual vaccination, vaccination early in the year (September to October), and greater cumulative number of vaccinations were associated with larger reductions in the risk of death compared with intermittent vaccination. Conclusions: In patients with HF, influenza vaccination was associated with a reduced risk of both all-cause and cardiovascular death after extensive adjustment for confounders. Frequent vaccination and vaccination earlier in the year were associated with larger reductions in the risk of death compared with intermittent and late vaccination.",
keywords = "communicable diseases, heart failure, influenza, human, prognosis, survival, therapeutics, vaccination",
author = "Daniel Modin and J{\o}rgensen, {Mads Emil} and Gunnar Gislason and Jensen, {Jan Skov} and Lars K{\o}ber and Brian Claggett and Hegde, {Sheila M.} and Solomon, {Scott D.} and Christian Torp-Pedersen and Tor Biering-S{\o}rensen",
year = "2019",
doi = "10.1161/CIRCULATIONAHA.118.036788",
language = "English",
volume = "139",
pages = "575--586",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams & Wilkins",
number = "5",

}

RIS

TY - JOUR

T1 - Influenza Vaccine in Heart Failure

T2 - Cumulative Number of Vaccinations, Frequency, Timing, and Survival: A Danish Nationwide Cohort Study

AU - Modin, Daniel

AU - Jørgensen, Mads Emil

AU - Gislason, Gunnar

AU - Jensen, Jan Skov

AU - Køber, Lars

AU - Claggett, Brian

AU - Hegde, Sheila M.

AU - Solomon, Scott D.

AU - Torp-Pedersen, Christian

AU - Biering-Sørensen, Tor

PY - 2019

Y1 - 2019

N2 - Background: Influenza infection is a serious event for patients with heart failure (HF). Little knowledge exists about the association between influenza vaccination and outcome in patients with HF. This study sought to determine whether influenza vaccination is associated with improved long-term survival in patients with newly diagnosed HF. Methods: We performed a nationwide cohort study including all patients who were >18 years of age and diagnosed with HF in Denmark in the period of January 1, 2003, to June 1, 2015 (n=134 048). We collected linked data using nationwide registries. Vaccination status, number, and frequency during follow-up were treated as time-varying covariates in time-dependent Cox regression. Results: Follow-up was 99.8% with a median follow-up time of 3.7 years (interquartile range, 1.7-6.8 years). The vaccination coverage of the study cohort ranged from 16% to 54% during the study period. In unadjusted analysis, receiving ≥1 vaccinations during follow-up was associated with a higher risk of death. After adjustment for inclusion date, comorbidities, medications, household income, and education level, receiving ≥1 vaccinations was associated with an 18% reduced risk of death (all-cause: hazard ratio, 0.82; 95% CI, 0.81-0.84; P<0.001; cardiovascular causes: hazard ratio, 0.82; 95% CI, 0.81-0.84; P<0.001). Annual vaccination, vaccination early in the year (September to October), and greater cumulative number of vaccinations were associated with larger reductions in the risk of death compared with intermittent vaccination. Conclusions: In patients with HF, influenza vaccination was associated with a reduced risk of both all-cause and cardiovascular death after extensive adjustment for confounders. Frequent vaccination and vaccination earlier in the year were associated with larger reductions in the risk of death compared with intermittent and late vaccination.

AB - Background: Influenza infection is a serious event for patients with heart failure (HF). Little knowledge exists about the association between influenza vaccination and outcome in patients with HF. This study sought to determine whether influenza vaccination is associated with improved long-term survival in patients with newly diagnosed HF. Methods: We performed a nationwide cohort study including all patients who were >18 years of age and diagnosed with HF in Denmark in the period of January 1, 2003, to June 1, 2015 (n=134 048). We collected linked data using nationwide registries. Vaccination status, number, and frequency during follow-up were treated as time-varying covariates in time-dependent Cox regression. Results: Follow-up was 99.8% with a median follow-up time of 3.7 years (interquartile range, 1.7-6.8 years). The vaccination coverage of the study cohort ranged from 16% to 54% during the study period. In unadjusted analysis, receiving ≥1 vaccinations during follow-up was associated with a higher risk of death. After adjustment for inclusion date, comorbidities, medications, household income, and education level, receiving ≥1 vaccinations was associated with an 18% reduced risk of death (all-cause: hazard ratio, 0.82; 95% CI, 0.81-0.84; P<0.001; cardiovascular causes: hazard ratio, 0.82; 95% CI, 0.81-0.84; P<0.001). Annual vaccination, vaccination early in the year (September to October), and greater cumulative number of vaccinations were associated with larger reductions in the risk of death compared with intermittent vaccination. Conclusions: In patients with HF, influenza vaccination was associated with a reduced risk of both all-cause and cardiovascular death after extensive adjustment for confounders. Frequent vaccination and vaccination earlier in the year were associated with larger reductions in the risk of death compared with intermittent and late vaccination.

KW - communicable diseases

KW - heart failure

KW - influenza, human

KW - prognosis

KW - survival

KW - therapeutics

KW - vaccination

U2 - 10.1161/CIRCULATIONAHA.118.036788

DO - 10.1161/CIRCULATIONAHA.118.036788

M3 - Journal article

C2 - 30586760

AN - SCOPUS:85060567006

VL - 139

SP - 575

EP - 586

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 5

ER -

ID: 223974323